The combination of serum miR‐96‐5p and CTSB represents potential serum biomarkers for cognitive impairment, and targeting the neuronal miR‐96‐5p/CTSB pathway may serve as a promising therapeutic strategy for AD. The gene discussed is CTSB; the disease is Alzheimer disease.